STOCK TITAN
  1. Home
  2. APTN

Adaptin Bio (APTN) Stock Price, News & Analysis

APTN OTC
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
1 13 sessions, May 14, 2026 to August 19, 2026
Largest daily move
+7.1% close of May 20, 2026
1-month change
+0.3% closing prices, July 14, 2026 to August 19, 2026

Company Description

APTN gained 0.3% in the month to August 19, 2026. The last closing price was $6.27.

For FY2025, Adaptin Bio reported diluted earnings per share of -$0.66.

This page collects what Stock Titan holds for APTN, including price data, latest news, SEC filings, and financial highlights.

Stock Performance

Chart
$6.27
No recent trading
Last close: August 19, 2026
+0.3%
1 month to August 19, 2026
-
Market Cap
-
Shares outstanding

Adaptin Bio (APTN) closed at $6.27 on August 19, 2026. In the month to August 19, 2026, the price gained 0.3%.

See what a $1,000 investment in APTN would be worth today

Average down calculator for APTN

APTN Metrics & Rankings

August 2026
+0.3%
—

Price returns through August 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

View All
—

Adaptin Bio Announces Opening of Enrollment in a Phase 1 Clinical Trial Evaluating Treatment of Malignant Brain Tumors with APTN-101

clinical trial
—

Adaptin Bio Shares (Ticker: APTN) Commence Trading on the OTCQB

Adaptin Bio has 2 recent news articles. Key topics include clinical trial. View all APTN news →

SEC Filings

View All

[424B3] Adaptin Bio (OTCQB: APTN) clears investor resale with no cash to company

[EFFECT] ADAPTIN BIO, INC. SEC Filing

[S-1] Adaptin Bio (OTCQB: APTN) details going‑concern risk amid resale

[424B3] Adaptin Bio (OTCQB: APTN) opens first-in-human brain cancer trial

[8-K] Adaptin Bio (APTN) starts brain cancer trial after 70–80% eradication in mice

[424B3] Adaptin Bio (OTCQB: APTN): going‑concern doubt, 4.1M shares for resale

[10-Q] Adaptin Bio (APTN) posts $2.35M loss and warns of going-concern risk

[EFFECT] ADAPTIN BIO, INC. SEC Filing

[POS AM] Adaptin Bio (APTN) files S-1 amendment for 4.1M-share resale overhang

[424B3] Adaptin Bio (APTN) registers 1.9M common shares and 2.23M warrant shares

Adaptin Bio has filed 10 recent SEC filings, including 4 Form 424B3, 2 Form EFFECT, 1 Form S-1, 1 Form 8-K. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all APTN SEC filings →

Financial Highlights

View Full Financials

Adaptin Bio reported diluted earnings per share of -$0.66 in FY2025. The current ratio was 0.29, measuring current assets divided by current liabilities.

-$0.66
Diluted EPS (FY2025)
0.29
Current Ratio
—
Revenue (FY2025)
—
Net Income (FY2025)
—
Operating Cash Flow
—
Net Profit Margin

Upcoming Events

No upcoming events scheduled for APTN.

Frequently Asked Questions

Adaptin Bio (APTN) has no recent trading. Its last close was $6.27 on August 19, 2026.

The diluted earnings per share (EPS) of Adaptin Bio (APTN) is -$0.66 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The current ratio of Adaptin Bio (APTN), current assets divided by current liabilities, was 0.29 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.